A multi-criteria decision analysis on the value of nintedanib for interstitial lung diseases.
Zozaya N, Arrizubieta Basterrechea MI, Bollo E, Castellví I, Espín J, Ortego N, Poveda-Andrés JL, Rodríguez Portal JA, Rivero A, Marcos-Rodríguez JA, Verde L.
Zozaya N, et al. Among authors: espin j.
Int J Technol Assess Health Care. 2022 Aug 1;38(1):e64. doi: 10.1017/S0266462322000459.
Int J Technol Assess Health Care. 2022.
PMID: 35912833
Free article.